資源描述：
《替吉奧聯(lián)合順鉑治療晚期胃癌的近期療效觀察.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫。
1、中國腫瘤臨床與康復(fù)2012年1O月第19卷第5期ChinJClinOncolRehabil，October2012，Vol19，No．5·425··臨床應(yīng)用·替吉奧聯(lián)合順鉑治療晚期胃癌的近期療效觀察時(shí)淑珍曲范杰于韋韋張捷(大連市第三人民醫(yī)院腫瘤內(nèi)科，大連116033)【摘要】目的探討替吉奧聯(lián)合順鉑治療晚期胃癌的有效性和安全性。方法采用非盲法隨機(jī)對(duì)照試驗(yàn)。治療組27例，替吉奧膠囊根據(jù)體表面積給藥，<1．25m，40mg，bid；1．25—1．50m，50mg，bid；>1．50m，60mg，bid，早晚餐后口服，d1～d14。順鉑：75mg／m，dl—d3，21d為一療程。對(duì)照
2、組26例，5一Fu600mg·m～·d以微量泵進(jìn)行持續(xù)靜脈滴注，d1～d5；順鉑20mg·m一·d～，靜脈滴注，d1一d5。28d為一療程。每完成2個(gè)周期復(fù)查評(píng)價(jià)療效和生活質(zhì)量狀況，觀察并記錄不良反應(yīng)。結(jié)果治療組有效率為59．3％，對(duì)照組為19．2％，兩組間比較差異有統(tǒng)計(jì)學(xué)意義(P=0．005)。臨床獲益率比較，治療組為88．9％，對(duì)照組為53．8％，兩組間比較差異有統(tǒng)計(jì)學(xué)意義(P=0．006)。治療前后治療組與對(duì)照組患者KPS評(píng)分改善情況差異有統(tǒng)計(jì)學(xué)意義(P=0．035)，治療后對(duì)照組KPS評(píng)分降低較治療組有顯著性差異(P=0．006)。兩組患者主要不良反應(yīng)為消化道毒性、血
3、液學(xué)毒性和肝臟毒性，兩組間比較差異無統(tǒng)計(jì)學(xué)意義(P>0．05)。結(jié)論替吉奧聯(lián)合順鉑治療晚期胃癌安全、有效?！娟P(guān)鍵詞】胃腫瘤；替吉奧；順鉑；藥物療法【中圖分類號(hào)】R735．2【文獻(xiàn)標(biāo)識(shí)碼】A【文章編號(hào)】1005—8664(2012)05-0425-03Short··termclinalinvestigationofcombinationchemotherapywithTS-1and~splatinonadvancedgastriccancerSHIShu-zhen，QuFan-fie，YUWei—wei，etal(DepartmentofOncology，theThirdPeo
4、ple’sHospitalofDalian，Dalian116033，China)【Abstract】ObjectiveToevaluatetheefectivenessandsafetyofcombinationchemotherapywithTS一1andcisplatinonadvancedgastriccancer．MethodsWeconductedanon—blinded，randomized，con—trolledtrial，53patientswithadvancedgastriccancerwererandomlyassignedtotwogroups．Th
5、etreatmentgroup(n=27)administeredwithTS一1capsule(dosesbasedonpatientsbodysurfacearea：<1．25m，40mg，bid；1．25～1．50m，50mg，bid；>1．50m，60mg，bid，fromday1to14)pluscisplatin(75mg／mfromday1throughday3)every21days．Thecontrolgroup(n=26)administeredwith5-Fu600mg／(m·d)intravenousdripfromday1today5bymicro—
6、pumpinfusioncontinuouslyandcisplatin20mg／(m·d)intravenousdriponday1today5every28days．Theresponserate，lifequalityandadversereactionwereevaluatedafterevery2cycles．ResultsInthetreatmentgrouptheeffectiverate(59．3％)，clinicalbeneficialrate(88．9％)andimprovementoflifequality(44．4％)weresignificantly
7、higherthanthoseofthecontrolgrouprespectly(P<0．05)．Thedecreaseoflifequalityweref0undin46．2％ofthecontrolgroupand11．1％ofthetreatmentgroup(P<0．05)．Themainadverseeventswerealimentarycanaltoxicity，hematologicsystemandhepatotoxicity．Therewasnosignificantdiferen
